WHO WE ARE
We are BeyondSpring, Inc., a global, clinical-stage bio-pharmaceutical company headquartered in New York.
WHAT WE DO
We develop innovative immuno-oncology cancer therapies with a robust pipeline from internal development and collaboration with the University of Washington in de novo drug discovery using an ubiquitination platform. Our lead asset, plinabulin, is in two phase 3 global clinical trials as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and the prevention of chemotherapy-induced neutropenia (CIN).
Since 2010, we’ve been on a mission to develop transformative cancer therapies that improve clinical outcomes for patients with high unmet needs.